3223-20-9

Basic information

• Product Name: Benzoyl chloride, 2-hydroxy-5-nitro-
• CAS NO: 3223-20-9
• Molecular Formula: C7H4ClNO4
• Molecular Weight: 201.566
• Mol File: 3223-20-9.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: Benzoyl chloride, 2-hydroxy-5-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 2-hydroxy-5-nitro-(3223-20-9)
• EPA Substance Registry System: Benzoyl chloride, 2-hydroxy-5-nitro-(3223-20-9)

Safety Data

• Hazardous Substances Data: 3223-20-9(Hazardous Substances Data)

Upstream product

• 96-97-9 5-nitrosalicylic acid 
• 69-72-7 salicylic acid 

Downstream Products

• 74688-65-6 N-(5-chloro-thiazol-2-yl)-2-hydroxy-5-nitro-benzamide 
• 74688-64-5 N-(5-bromo-thiazol-2-yl)-2-hydroxy-5-nitro-benzamide 
• 74675-84-6 2-hydroxy-5-nitro-N-(4-phenyl-thiazol-2-yl)-benzamide 
• 74688-66-7 2-(2-hydroxy-5-nitro-benzoylamino)-4-methyl-thiazole-5-carboxylic acid ethyl ester 
• 74675-85-7 N-[4-(4-chloro-phenyl)-thiazol-2-yl]-2-hydroxy-5-nitro-benzamide 
• 67127-27-9 2-hydroxy-5-nitro-N-(1⁽²⁾H-tetrazol-5-yl)-benzamide 
• 80780-59-2 N-Butyl-N-[4-(6,7,9,10,12,13,15,16,18,19-decahydro-5,8,11,14,17,20-hexaoxa-benzocyclooctadecen-2-ylazo)-phenyl]-2-hydroxy-5-nitro-benzamide 
• 68507-73-3 (2-hydroxy-5-nitrophenyl)(piperidin-1-yl)methanone 
• 114259-81-3 (2-hydroxy-5-nitrophenyl)(4-methylpiperidin-1-yl)methanone 
• 68507-72-2 (2-hydroxy-5-nitrophenyl)(morpholino)methanone 
• 17302-46-4 methyl 2-hydroxy-5-nitrobenzoate 

Relevant articles and documents

Cathepsin B inhibitors: Further exploration of the nitroxoline core

Human cathepsin B is a cysteine protease with many house-keeping functions, such as intracellular proteolysis within lysosomes. Its increased activity and expression have been strongly associated with many pathological processes, including cancers. We present here the design and synthesis of novel derivatives of nitroxoline as inhibitors of cathepsin B. These were prepared either by omitting the pyridine part, or by modifying positions 2, 7, and 8 of nitroxoline. All compounds were evaluated for their ability to inhibit endopeptidase and exopeptidase activities of cathepsin B. For the most promising inhibitors, the ability to reduce extracellular and intracellular collagen IV degradation was determined, followed by their evaluation in cell-based in vitro models of tumor invasion. The presented data show that we have further defined the structural requirements for cathepsin B inhibition by nitroxoline derivatives and provided additional knowledge that could lead to non-peptidic compounds with usefulness against tumor progression.

Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents

A critical question in natural product-based drug discovery is how to translate the product into drug-like molecules with optimal pharmacological properties. The generation of natural product-inspired scaffold diversity is an effective but challenging strategy to investigate the broader chemical space and identify promising drug leads. Extending our efforts to the natural product evodiamine, a diverse library containing 11 evodiamine-inspired novel scaffolds and their derivatives were designed and synthesized. Most of them showed good to excellent antitumor activity against various human cancer cell lines. In particular, 3-chloro-10-hydroxyl thio-evodiamine (66c) showed excellent in vitro and in vivo antitumor efficacy with good tolerability and low toxicity. Antitumor mechanism and target profiling studies indicate that compound 66c is the first-in-class triple topoisomerase I/topoisomerase II/tubulin inhibitor. Overall, this study provided an effective strategy for natural product-based drug discovery. (Figure Presented).

N-BENZYLANILINE DERIVATIVE AND USES THEREOF

Disclosed are an N-benzylaniline derivative and uses thereof. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has an action of protecting against cerebral ischemia/reperfusion injury and an